rEVO Biologics, Inc. announces enrollment of first patient in phase III trial of ATryn to treat early onset preeclampsia

24-07-2014 Business Wire HealthComments (0)

AtrynBiotechnologyLFB BiotechnologiesPharmaceuticalUSAWomen's Health

rEVO Biologics, Inc., a subsidiary of LFB Biotechnologies, today announced the enrollment of the first patient in its Phase 3 clinical trial of ATryn [antithrombin (Recombinant)], for the treatment of preeclampsia during the 24th to 28th week of pregnancy, or early onset preeclampsia. The objective of the PRESERVE-1 trial is to assess whether ATryn prolongs pregnancy in mothers with early onset preeclampsia, consequently reducing the high rates of neonatal m

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top